Lemborexant, a Dual Orexin Receptor Antagonist, ameliorates Tau‐mediated Sleep Loss and Neurodegeneration
Samira Parhizkar, Wei Chen, Xin Bao, Grace Gent, Nicholas Rensing, Eric Tycksen, Emily Franke, Melissa Manis, Megan E Bosch, Choonghee Lee, Javier R Serrano, Eric Landsness, Michael Wong, David M Holtzman · 2025
Read Lemborexant, a Dual Orexin Receptor Antagonist, ameliorates Tau‐mediated Sleep Loss and Neurodegeneration by Samira Parhizkar, Wei Chen, Xin Bao, Grace Gent, Nicholas Rensing, Eric Tycksen, Emily Franke, Melissa Manis, Megan E Bosch, Choonghee Lee, Javier R Serrano, Eric Landsness, Michael Wong, David M Holtzman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710117.txt.
Description
Samira Parhizkar and co-authors report a 2025 conference abstract on a sleep drug tested in mice with tau disease. Poor sleep can feed tau buildup and brain inflammation. The drug, lemborexant, blocks orexin signals and promotes sleep in mice and humans. The team gave it daily to mice bred with tau changes and the APOE4 risk gene.
Treatment restored lost deep sleep and sharply cut harmful tau deposits. A blood marker of nerve damage fell, and brain shrinkage eased compared with untreated mice. The results suggest that fixing sleep may slow tau-driven damage, not just ease its symptoms.
Catalog record
| CREATOR | Samira Parhizkar, Wei Chen, Xin Bao, Grace Gent, Nicholas Rensing, Eric Tycksen, Emily Franke, Melissa Manis, Megan E Bosch, Choonghee Lee, Javier R Serrano, Eric Landsness, Michael Wong, David M Holtzman |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |